A study published in the Journal of Clinical Oncology found that a continuous dosing schedule of PEG-asparaginase (PEGasp) in children with acute lymphoblastic leukemia (ALL) reduced hypersensitivity reactions and antibody formation compared to a noncontinuous schedule. The study included 818 patients aged 1-18, with 312 in the medium-risk arm. Results showed fewer hypersensitivity reactions in the continuous schedule group, with no change in efficacy. The continuous dosing schedule also led to lower antibody levels and inactivating reactions. Overall, continuous PEGasp dosing was deemed effective in preventing allergic reactions and antibody formation in pediatric ALL treatment.
Source link
Continuous PEG-Asparaginase Dosing Reduces Hypersensitivity Reactions in Pediatric ALL
